Literature DB >> 20549176

[Calcitonin determination for early diagnosis of medullary thyroid cancer].

W Karges1.   

Abstract

Calcitonin is considered to be a sensitive marker for medullary thyroid cancer (MTC) therefore early detection and surgical treatment may help to improve the clinical prognosis of MTC. Routine calcitonin measurement has therefore been recommended in the diagnostic evaluation of patients with nodular thyroid disease. In the case of elevated serum calcitonin (>20 pg/ml) stimulation testing is recommended to improve the predictive power for MTC particularly in patients with small nodules. Serum calcitonin measurement cannot reliably discriminate between micro-MTC (<10 mm) and C cell hyperplasia. In patients with stimulated calcitonin levels exceeding 100 pg/ml thyroidectomy is recommended because of a high inherent risk of MTC. Highly elevated basal and stimulated serum calcitonin levels are strongly suggestive of MTC with practical implications for surgical management.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20549176     DOI: 10.1007/s00104-009-1883-9

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  28 in total

1.  Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases.

Authors:  J R Hahm; M S Lee; Y K Min; M K Lee; K W Kim; S J Nam; J H Yang; J H Chung
Journal:  Thyroid       Date:  2001-01       Impact factor: 6.568

2.  Medicare and cost-effectiveness analysis.

Authors:  Peter J Neumann; Allison B Rosen; Milton C Weinstein
Journal:  N Engl J Med       Date:  2005-10-06       Impact factor: 91.245

3.  Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study.

Authors:  G Papi; S M Corsello; K Cioni; A M Pizzini; S Corrado; C Carapezzi; G Fadda; A Baldini; C Carani; A Pontecorvi; E Roti
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

4.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

5.  Micromedullary thyroid cancer: how micro is truly micro?

Authors:  Venu G Pillarisetty; Steven C Katz; Ronald A Ghossein; R Michael Tuttle; Ashok R Shaha
Journal:  Ann Surg Oncol       Date:  2009-07-01       Impact factor: 5.344

6.  Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders.

Authors:  H Vierhapper; B Niederle; C Bieglmayer; K Kaserer; S Baumgartner-Parzer
Journal:  Thyroid       Date:  2005-11       Impact factor: 6.568

7.  Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels.

Authors:  Maurizio Iacobone; Patricia Niccoli-Sire; Frederic Sebag; Catherine De Micco; Jean-François Henry
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

8.  Sporadic hypercalcitoninemia: clinical and therapeutic consequences.

Authors:  C Scheuba; K Kaserer; A Moritz; R Drosten; H Vierhapper; C Bieglmayer; O A Haas; B Niederle
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

9.  Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer.

Authors:  Andreas Machens; Florian Hoffmann; Carsten Sekulla; Henning Dralle
Journal:  Endocr Relat Cancer       Date:  2009-09-02       Impact factor: 5.678

10.  Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels.

Authors:  F Milone; V Ramundo; M G Chiofalo; R Severino; I Paciolla; L Pezzullo; G Lombardi; A Colao; A Faggiano
Journal:  Clin Endocrinol (Oxf)       Date:  2009-12-18       Impact factor: 3.478

View more
  4 in total

Review 1.  [Surgical therapy for thyroid gland malignancies].

Authors:  P E Goretzki; K Schwarz; B Lammers
Journal:  HNO       Date:  2013-01       Impact factor: 1.284

Review 2.  [Thyroid C cells and their pathology: Part 2: Medullary thyroid carcinoma].

Authors:  S Synoracki; S T Schmid; S Ting; K W Schmid
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

Review 3.  Endocrine neoplasms in familial syndromes of hyperparathyroidism.

Authors:  Yulong Li; William F Simonds
Journal:  Endocr Relat Cancer       Date:  2016-05-20       Impact factor: 5.678

4.  Incidental diagnosis of medullary thyroid carcinoma due to persistently elevated procalcitonin in a patient with COVID-19 pneumonia: A case report.

Authors:  Amitabha Saha; Madhusha Mukhopadhyay; Souvik Paul; Arnab Bera; Tapas Bandyopadhyay
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.